Nowadays, immune checkpoint inhibitors (ICI) have become the cornerstone of treatment for
many tumors, either as monotherapy or in combination with other therapies. However, these …

Immune checkpoint inhibitor (ICI) treatment has dramatically revolutionized the landscape of
therapeutic approaches in multiple cancers, particularly, non-small-cell lung cancer …

The use of immune checkpoint inhibitors is revolutionising the treatment of cancer. However,
their unique toxicity profile is substantially different from what has been observed with …

Background The use of immune checkpoint inhibitors (ICI) has revealed a new panel of
tumor response and adverse events. Immune-related sarcoidosis-like reactions is frequently …

Introduction Immune checkpoint inhibitors are one of the standard treatments for metastatic
renal cell carcinoma. Among immune‐related adverse events, the sarcoidosis‐like reaction …

Monoclonal antibodies directed against immune checkpoint proteins have been widely used
to treat various cancers and have resulted in favorable clinical outcomes. Despite these …

Tumor‐related sarcoidosis‐like reactions (SLR) have been reported with the use of immune
checkpoint inhibitors (ICIs). We report a case of 50‐year‐old woman who observed an …

Background Immune checkpoint inhibitors (ICI) have been associated with several immune-
related adverse events, including sarcoidosis-like reactions (SLR). SLR, which has a low …

With the development of immunotherapy, immune checkpoint inhibitors (ICIs) are widely
used in clinical oncology and have achieved good results. ICIs could induce immune-related …

Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor
types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer …